With regard to adjunctive therapies, the use of lomitapide (an MTP inhibitor) or evinacumab (an ANGPTL3 inhibitor) was considered for eligible patients with refractory hypercholesterolemia. Here, ANGPTL3 is linked to familial hypercholesterolemia.